seldegamadlin

Seldegamadlin is an investigational small-molecule proteolysis-targeting chimera (PROTAC) that functions as a potent MDM2 degrader and p53 stabilizer for the treatment of cancers with intact p53. By recruiting the E3 ligase cereblon to MDM2, seldegamadlin induces ubiquitination and proteasomal degradation of MDM2, thereby disrupting the MDM2–p53 negative feedback loop, restoring p53 tumor suppressor activity, and triggering apoptosis and growth arrest in malignant cells.[16][20][21] It is being explored preclinically for hematologic malignancies such as acute myeloid leukemia and acute lymphoblastic leukemia, as well as solid tumors.[16][20][21]